Pharmacological significance of triazole scaffold

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 1, 2011, Pages 1-21

  Kharb, Rajeev ^a   Sharma, Prabodh Chander ^b   Yar, Mohammed Shahar ^c  

^a Sanjivani College of Pharmaceutical Sciences   (India)

^b KURUKSHETRA UNIVERSITY   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

1,2,3 triazole; 1,2,4 triazole; pharmacological activities

Indexed keywords

1 [5 METHYL 1 [8 (TRIFLUOROM ETHYL)QUINOLIN 5 YL] 1H 1,2,3 TRIAZOL 4 YL] 3 PHENYLPROP 2 EN 1 ONE; 1,2,3 TRIAZOLE DERIVATIVE; 1,2,4 OXADIAZOLE DERIVATIVE; 1,2,4 TRIAZOLE DERIVATIVE; 2 (3 FLUOROPHENYL) 1 [[1 (2,3,4, TRIFLUOROPHENYL) 1H 1,2,3 TRIAZOL 4 YL]METHYL] 1H BENZIMIDAZOLE; 2 (AMINOMETHYL) 4 [[ 1H PYRAZOL 4 YLMETHYLIDENE]AMINO] 2,4 DIHYDRO 3H 1,2,4 TRIAZOLE 3 THIONE; 3 (METHYLSULPHONYL) 5 PHENYL 1H 1,2,4 TRIAZOLE; 3 [1 (PIPERIDIN 4 YL) 1H 1,2,3 TRIAZOL 4 YL] 1,2,4 OXADIAZOL 5(4H) ONE; 5 [(BIPHENYL 4 YLOXY)METHYL] 4 (4 CHLOROPHENYL) 4H 1,2,4 TRIAZOLE 3 THIOL; 7 BENZYLIDENE 6 (2,4 DICHLORO 5 FLUOROPHENYL) 7H [1,2,4]TRIAZOLO[3,4 B][1,3,4]THIADIAZINE; ANALGESIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CICLOPIROXOLAMINE; CIPROFLOXACIN; FLUCONAZOLE; FLURBIPROFEN; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; N (4 CHLOROPHENYL) 3 [2 (4 NITRO 1H IMIDAZOL 1 YL)ETHYL] 1H 1,2,4 TRIAZOL 5 AMINE; NEOMYCIN; POSACONAZOLE; RIFAMPICIN; TRIAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANALGESIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CELL NUCLEUS; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; HUMAN; IMMUNOMODULATION; LOCAL ANESTHESIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIUM MARNEFFEI; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TRICHOPHYTON MENTAGROPHYTES;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; PHARMACEUTICAL PREPARATIONS; RATS; TRIAZOLES;

EID: 79851483355     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903524304     Document Type: Article

References (157)

1. Holla BS, Mahalinga M, Karthikeyen MS, Poojary B, Akberali PM, Kumari NS. Synthesis, characterization and antimicrobial activity of some substituted 1,2,3-triazoles. Eur J Med Chem 2005;40:1173-1178. (Pubitemid 41446290)
2. Sanghvi YS, Bhattacharya BK, Kini GD, Matsumoyo SS, Larson SB, Jolley WB, Robins RK, Revankar GR. Growth inhibition and induction of cellular diferentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin. J Med Chem 1990;33:336-344. (Pubitemid 20038214)
3. Chen MD, Lu SJ, Yuag GP, Yang SY, Du XL. Synthesis and antimicrobial activity of some heterocyclic beta-enamino ester derivatives with 1,2,3-triazole. Heterocyclic Comm 2000;6:421-426.
4. Sherement EA, Tomanov RI, Trukhin EV, Berestovitskaya VM. Synthesis of 4-aryl-5-nitro-1,2,3-triazoles. Russ J Org Chem 2004;40:594-595. (Pubitemid 39060973)
5. Hafez HN, Abbas HA, El-Gazzar AR. Synthesis and evaluation of analgesic, anti-infammatory and ulcerogenic activities of some triazolo-and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines. Acta Pharm 2008;58:359-378.
6. Banu KM, Dinaker A, Ananthnarayan C. Synthesis, characterization of antimicrobial studies and pharmacological screening of some substituted 1,2,3-triazoles. Indian J Pharm Sci 1999;61:202-205.
7. Guan LP, Jin QH, Tian GR, Chai KY, Quan ZS. Synthesis of some quinoline-2(1 H)-one and 1,2,4-triazolo [4,3-a]quinoline derivatives as potent anticonvulsants. J Pharm Sci 2007;10:254-262.
8. Passannanti A, Diana P, Barraja P, Mingooia F, Lauria A, Cirrincine G. Pyrrolo[2,3-d][1,2,3]triazoles as potential antineoplastic agents. Heterocycles 1998;48:1229-1235. (Pubitemid 128657650)
9. Gujjar R, Marwaha A, White J, White L, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, Charman S, Rathod PK, Phillips MA. Identifcation of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 2009;52:1864-1872.
10. Johns BA, Weatherhead JG, Allen SH, Tompson JB, Garvey EP, Foster SA. Te use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 2009;19:1802-1806.
11. Manfredini S, Vicentini CB, Manfrini M, Bianchi N, Rustigliano C, Mischiati C, Gambari R. Pyrazolo-triazoles as light DNA cleaving agents. Bioorg Med Chem 2000;8:2343-2346. (Pubitemid 30642758)
12. Duran A, Dogan HN, Rollas H. Synthesis and preliminary anticancer activity of new 1,4-Dihydro-3-(3-hydroxy-2-naphthyl)-4-substituted-5H-1,2,4- triazoline-5-thiones. Farmaco 2002;57:559-564. (Pubitemid 34765748)
13. Sztanke K, Tuzimski T, Rzymowska J. Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem 2008;43:404-419. (Pubitemid 351215604)
14. Gilchrist TL. Heterocyclic Chemistry. Singapore: Pearson Education India, 2005:298-307.
15. Liu P, Zhu S, Xie W. Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents. Bioorg Med Chem Lett 2008;18:3261-3265. (Pubitemid 351718338)
16. Holmes CB, Losina E, Walensky RP. Review of human immunodefciency virus type I-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003;36:652-662. (Pubitemid 36259573)
17. Brumftt W, Hamilton-Muller JMT. Te challenges of methicillin-resistant Staphylococcus aureus. J Drug Exp Clin Res 1994;20:215-224.
18. Neu HC. Te crisis in the antibiotic resistance. Science 1992;257: 1064-1074.
19. Vicini P, Geronikaki A, Anastasia K, Incerti M Zani F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. Bioorg Med Chem 2006;14:3859-3864.
20. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;94:499-511. (Pubitemid 26366535)
21. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79. (Pubitemid 29055953)
22. Demir-Erol D, Calis U, Demirdamar R, Nulug N, Ertan M. Synthesis and biological activities of some 3,6-disubstituted-thiazolo[3,2-b] [1,2,4]triazoles. J Pharm Sci 1995;84:462-465.
23. Jana C, Julius S. Resistance in fuconazole-resistant Candida albicans, isolates from vaginal candidiasis. Int J Antimicrob Agents 2006;27:403-408.
24. Kaufmann C, Hedderwick SA. Treatment of systemic fungal infections in older patients: achieving optimal outcomes. Drugs Aging 2001;18:313-324.
25. Linnbur SA, Parnes BL. Pulmonary and hepatic toxicity due to nitrofurantoin and fuconazole treatment. Ann Pharmacother 2004;38:612-616. (Pubitemid 38352225)
26. Sheng C, Zhang W, Ji H, Zhang M, Song Y, Xu H, Zhu J, Miao Z, Jiang Q, Zhou Y Zhu J, Lu J. Structure based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J Med Chem 2006;49:2512-2525.
27. Boyle FT, Gilman DJ, Gravestock MB, Wardleworth JM. Synthesis and structure activity relationships of a novel antifungal agent ICI 195739. Ann NY Acad Sci 1988;544:86-100. (Pubitemid 19259308)
28. Parke JS, Yu KA, Kang TH, Kim S, Toung-Gersuh YG. Discovery of novel imidazole-linked triazoles as antifungal agents. Bioorg Med Chem Lett 2007;17:3486-3490. (Pubitemid 46819010)
29. Lebouvier N, Pegniez F, Dufos M, Borgne LE. Synthesis and antifungal activities of new fuconazole analogues with azaheterocycle moiety. Bioorg Med Chem Lett 2007;17:3686-3689. (Pubitemid 46908777)
30. Demirayak S., Benkli K., Guven K. Synthesis and antimicrobial activities of some 3-arylamino-5-[2-(substituted imidazole-1-yl or benzimidazol-1-yl)ethyl] -1,2,4-triazole derivatives. Eur J Med Chem 2000;35:1037-1040.
31. Gill C, Jadhav G, Shaikh M, Kale R. Clubbed [1,2,3] triazoles by fuorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. Bioorg Med Chem Lett 2008;18:6244-6247.
32. Zitouni GT, Chevallet P, Kaya D. Synthesis and antimicrobial activity of 4-phenyl/cyclohexyl-5-(1-phenoxyethyl)-3-[N-(2-thiazolyl)acetamido]thio-4H-1,2, 4-triazole derivatives. Eur J Med Chem 2005;40:607-613. (Pubitemid 40732529)
33. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T. Design, synthesis, and evaluation of novel fuoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 2009;52:2243-2254.
34. Pintilie O, Profre L, Sunel V, Popa M, Pui A. Synthesis and antimicrobial activity of some new 1,3,4-thiadiazole and 1,2,4-triazole compounds having a D,L-methionine moiety. Molecules, 2007;12:103-113.
35. Holla BS, Rao BS, Sarojini BK, Akberali PM, Kumari NS. Synthesis and studies of some new fuorine containing triazolothiadiazines as possible antibacterial, antifungal and anticancer agents. Eur J Med Chem 2006;41:657-663.
36. Sangshetti JN, Nagawade RR, Shinde DB. Synthesis of novel 3-(1-(1-substituted piperidin-4-yl)-1 H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol- 5(4H)-one as antifungal agents. Bioorg Med Chem Lett. 2009;19:3564-3567.
37. Isloor AM, Kalluraya B, Shetty P. Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1,2,4-triazoles. Eur J Med Chem 2009;44:3784-3787.
38. Xie W, Chipman DL, Robertson RL, Erikson DL. Expression of mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696. (Pubitemid 21916484)
39. Kajubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. Regulation of COX-2 expression in human cancers. J Biol Chem 1991;266:12866-12872.
40. Hinz B, Brune KJ. cyclooxygenase-2: 10 years later. J Pharm Exp Ter 2002;300:367-375.
41. DeWitt DL. COX-2 selective inhibitors: new super aspirins. Mol Pharmacol 1999;55:625-631.
42. Mitchell JA, Akarasereenont C, Tiemermann RJ, Flower JR, Vane JR. Selectivity of nonsteroidal anti-infammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697. (Pubitemid 24008705)
43. Tozkoparan B, Kupeli E, Yesilada E, Ertan M. Preparation of 5-aryl-3-alkylthio-l,2,4 triazoles and corresponding sulfones with antiinfammatory-analgesic activity. Bioorg Med Chem 2007;15:1808-1814. (Pubitemid 46394040)
44. Kumar H, Javed SA, Khan SA. 1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties. Eur J Med Chem 2008;43:2688-2698.
45. Mohamed BG, Abdel-Alim AA, Hussein MA. Synthesis of 1-acyl-2-alkylthio-1, 2,4-triazolobenzimidazoles with antifungal, anti-infammatory and analgesic efects. Acta Pharm 2006;56:31-48. (Pubitemid 43253971)
46. Abdel-Rahman HM, Hussein MA. Synthesis of beta-hydroxypropanoic acid derivatives as potential anti-infammatory, analgesic and antimicrobial agents. Arch Pharm 2006;339:378-387. (Pubitemid 44213728)
47. Wuest F, Tang X, Kniess T, Pietzsch J, Suresh M. Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)- methanesulfonylphenyl derivatives. Bioorg Med Chem 2009;17:1146-1151.
48. Moise M, Sunel V, Profre L, Popa M, Desbrieres J, Peptu C. Synthesis and biological activity of some new 1,3,4-thiadiazole and 1,2,4-triazole compounds containing a phenylalanine moiety. Molecules 2009;14:2621-2631.
49. UK Cancer Incidence Statistics by Age. Cancer Research UK. 2007:6-25
50. Cancer. World Health Organization. Feb, 2006:6-25.
51. Report sees 7.6 Million Global 2007 Cancer Deaths. American Cancer Society. December, 2007.
52. Edwards P J. Tiazolidinone derivatives targeting drug-resistant lung cancer cells. Drug Discovery Today 2008;13:1107-1108.
53. Zhai X, Zhao YF, Liu YJ, Zhang Y, Xun FQ, Liu J, Gong P. Synthesis and cytotoxicity studies of novel [1,2,4]triazolo[1,5-a]pyrimidine-7-amines. Chem Pharm Bull 2008;56:941-945. (Pubitemid 351949708)
54. McArthur HL, Gelmon KA, Olivotto IA, Speers CH, Ellard SL, OReilly SE, Kennecke HF. Efectiveness of a letter notifcation program for women with early-stage breast cancer eligible for extended adjuvant letrozole. J Clin Oncol 2009;27:1388-1393.
55. Ibrahim DA. Synthesis and biological evaluation of 3,6-disubstituted[1,2, 4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as a novel class of potential anti tumor agents. Eur J Med Chem 2009;44:2776-2781.
56. Lin R, Connolly PJ, Huang S. 1-Acyl-1 H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem 2005;48:4208-4211. (Pubitemid 40884921)
57. El-Hawash SA, Habib NS, Kassem MA. Synthesis of some new quinoxalines for evaluation of in vitro antitumor and antimicrobial activities. Arch Pharm 2006;339:564-571. (Pubitemid 44638521)
58. Zhang Q, Pan J, Zheng RL, Wang Q. Rediferentiation of human hepatoma cell induced by 6-(p-chlorophenyl)-3-[1-(p-chlorophenyl)-5-methyl-1 H-1,2,3-triazol-4-yl]-s-triazolo[3,4-b]-1,3,4-thiadiazole(TDZ). Pharmazie 2005;60:378-382. (Pubitemid 40676326)
59. Pachuta-Stec A, Rzymowska J, Mazur L, Mendyk E, Pitucha M, Rzaczyska Z. Synthesis, structure elucidation and antitumour activity of N-substituted amides of 3-(3-ethylthio-1,2,4-triazol-5-yl)propenoic acid. Eur J Med Chem 2009;44:3788-3793.
60. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-1209. (Pubitemid 41393598)
61. Poulsen SA, Wilkinson BL, Innocenti A. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzene sulphonamide derivatives. Bioorg Med Chem Lett 2008;18:4624-4627.
62. Tierney LM, McPhee SJ, Papadakis MA. Current Medical Diagnosis and Treatment. New York: Lange Medical Books/McGraw-Hill, 2002:1203-1215.
63. Rother KI. Diabetes treatment-bridging the divide. Engl J Med 2007;356:1499-1501.
64. Defnition, Diagnosis and Classifcation of Diabetes Mellitus and its Complications. Geneva, World Health Organization Department of Noncommunicable Disease Surveillance 1999.
65. Weiss J, Sumpio B. Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 2006;31:143-150. (Pubitemid 43078941)
66. Peek PM, Chrousos GP. Hypercortisolism and obesity. Ann NY Acad Sci 1995;771:665-676. (Pubitemid 26077444)
67. Chapman KE, Coutinho A, Gray M, Gilmour JS, Savill JS, Secki JR. Local amplifcation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type I and its role in infammatory response. Ann NY Acad Sci 2006;1088:265-273. (Pubitemid 47092051)
68. Zhu Y Olson SH, Graham D. Phenylcyclobutyl triazoles as selective inhibitors of 11ß-hydroxysteroid dehydrogenase type. Bioorg Med Chem Lett 2008;18:3412-3416. (Pubitemid 351718311)
69. Ebdrup S, Sorensen LG, Olsen OH, Jacobsen P. Synthesis and structure-activity relationship for a novel class of potent and selective carbamoyl-triazole based inhibitors of hormone sensitive lipase. J Med Chem 2004;47:400-410. (Pubitemid 38057883)
70. Strobl JS, Tomas MJ. Human growth hormone. Pharmacol Rev 1994;46:1-36.
71. Blenthen SL, Baptista J, Kuntze J, Foley T. Adult height in growth hormone (GH)-defcient children related with biosynthetic GH. J Clin Endocrinol Metab 1997;82:418-420. (Pubitemid 27068604)
72. Bouillane O, Rainfray M, Tissandier O, Nasr A. Growth hormone therapy in elderly people: An age-delaying drug. Fundamen Clin Pharmacol 1996;10:416-430. (Pubitemid 26330270)
73. Howard AD, Feighner SD, Cully DF, Arena JP. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-977. (Pubitemid 26275178)
74. Stark D, Treiber HJ, Schobel D. Preparation of 3-[(aminoalkyl)thio]-1,2, 4-triazoles on dopamine D3 receptors ligands. International patents WO 2000042038, 2000.
75. Chan C, Dagnino R, Huang CQ, McCarthy JR. 1-Alkyl-3-amino-5-aryl-1H-[1,2, 4-triazoles: novel synthesis via cyclization of N-acyl-S-methylisothoiureas with alkylhydrazines and their potent corticotrophin-releasing factor-1(CRF1) receptor antagonist activities. Bioorg Med Chem Lett 2001;11:3165-3168. (Pubitemid 33092015)
76. Wandsworth HJ, Jenkins SM, Orlek BS, Casidy F, Brown F. Synthesis and muscarinic activities of quinuclidine-3-yl-triazole and tetrazole derivatives. J Med Chem 1992;35:1280-1290.
77. Jenkins SM, Wandsworth HJ, Bromidge S, Orlek BS, Hawkins J. Substituent variation in azabicyclic triazole and tetrazole-based muscarinic receptor ligands. J Med Chem 1992;35:2392-2406.
78. Demange L, Boeglin D, Moulin A. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor-1. J Med Chem 2007;50:1939-1957. (Pubitemid 46626603)
79. Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004;113:224-230. (Pubitemid 39422599)
80. Gillett NA, Chan C. Applications of immunohistochemistry in the evaluation of immunosuppressive agents. Hum ExpToxicol 2000;19:251-254. (Pubitemid 30428175)
81. Lindstedt R, Ruggiero V, D'Alessio V, Manganello S, Petronzelli F, Stasi MA, Vendetti S, Assandri A, Carminati P, De Santis R. Te immunosuppressor st1959, a 3,5-diaryl-s-triazole derivative, inhibits T cell activation by reducing NFAT nuclear residency. Int J Immunopathol Pharmacol 2009;22:29-42.
82. Sieh H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82;291-295.
83. Aktay G, Tozkoparan B, Ertan M. Investigation of antioxidant properties of some 6-(alpha-aminobenzyl)thiazolo[3,2-b]-1,2,4-triazole-5-ol compounds. J Enzyme Inhib Med Chem 2008;27:1-5.
84. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr 2008;79:368-376. (Pubitemid 351441488)
85. Ongini E, Monopoli A, Cacciari B, Baraldi PG. Selective adenosine A2A receptor antagonist. Farmaco 2001;56:87-90.
86. Gursoy A, Terzioglu N. Synthesis and isolation of new regioisomeric 4-thiazolidinones and their anticonvulsant activity. Turk J Chem 2005;29:247-254. (Pubitemid 40993195)
87. Pandeya SN, Sriram D, Yogeeswari P, Stables JP. Anticonvulsant and neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives. Pharmazie 2001;56:875-876. (Pubitemid 33081723)
88. Karakurt A, Aytemir MD, Stables JP, Ozalp M, Betul Kaynak F, Ozbey S, Dalkara S. Synthesis of some oxime ether derivatives of 1-(2-naphthyl)-2-(1,2,4- triazol-1-yl)ethanone and their anticonvulsant and antimicrobial activities. Arch Pharm 2006;339:513-520. (Pubitemid 44534956)
89. Sun XY, Jin YZ, Li FN, Li G, Chai KY, Quan ZS. Synthesis of 8-alkoxy-4, 5-dihydro-[1,2,4]triazole[4,3-a]quinoline-1-ones and evaluation of their anticonvulsant properties. Arch Pharm Res 2006;29:1080-1085.
90. Husain A, Naseer MA, Sarafroz M. Synthesis and anticonvulsant activity of some novel fused heterocyclic 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives. Acta Pol Pharm 2009;66:135-140.
91. Siddiqui N, Alam MS, Ahsan W. Synthesis, anticonvulsant and toxicity evaluation of 2-(1 H-indol-3-yl)acetyl-N-(substituted phenyl)hydrazine carbothioamides and their related heterocyclic derivatives. Acta Pharm 2008;58:445-454.
92. Kucukguzel G, Kocatepe A, De Clercq E, Sahin F, Gulluce M. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from difunisal hydrazide. Eur J Med Chem 2006;41:353-359.
93. Snider DE, Raviglione M Jr, Kochi A. Global burden of tuberculosis, chapter 1. In: Tuberculosis:Pathogenisis, Protection, and Control. American society for Microbiology, Washington, DC 20005.1994:3-11.
94. Ballel L, Field RA, Duncan K, Young R. New small molecule synthetic antimycobacterials. Antimicrob Agents Chemotherapy 2005;49:2153-2163. (Pubitemid 40734441)
95. Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007;196:528-536.
96. Cottet F, Marull M, Lefebvre O. Recommendable routes to trifuoromethyl substituted pyridine and quinoline carboxylic acids. Eur J Org Chem 2003;8:1559-1568.
97. Abdel-Rahman HM, El-Koussi NA, Hassan HY. Fluorinated 1,2,4-Triazolo[1,5-a]pyrimidine-6-carboxylic acid derivatives as antimycobacterial agents. Arch Pharm 2009;342:94-99.
98. Shiradkar M, Suresh Kumar GV, Dasari V, Tatikonda S, Akula KC, Shah R. Clubbed triazoles: a novel approach to antitubercular drugs Eur J Med Chem 2007;42:807-816. (Pubitemid 46810067)
99. Kaplancikli TA, Turan-Zitouni G, Chevallet P. Synthesis and antituberculosis activity of new 3-alkylsulfanyl-1,2,4-triazole derivatives. J Enzyme Inhib Med Chem 2005;20:179-182. (Pubitemid 40645507)
100. Upadhayaya RS, Kulkarni GM, Vasireddy NR, Vandavasi JK, Dixit SS, Sharma V, Chattopadhyaya J. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg Med Chem 2009;17:4681-4692.
101. Jadhav GR, Shaikh MU, Kale RP, Shiradkar MR, Gill CH. SAR study of clubbed [1,2,4]-triazolyl with fuorobenzimidazoles as antimicrobial and antituberculosis agents. Eur J Med Chem 2009;44:2930-2935.
102. Barreca M L, Chimirri A, Luca LD, Monforte AM, Monforte P, Rao A, Zappala M, Balzarini J, Clercq ED, Pannecouque C, Witvrouw M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett 2001;11:1793-1796. (Pubitemid 32568322)
103. Rao A, Balzarini J, Carbone A, Chimirri A, Clercq ED, Monforte AM, Monforte P, Pannecouque C, Zappalà M. 2-(2,6-dihalophenyl)-3-(pyrimidin- 2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res 2004;63:79-84. (Pubitemid 39061772)
104. Rao A, Carbone A, Chimirri A, Clercq ED, Monforte AM, Monforte P, Pannecouque C, Zappala M. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Farmaco 2003;58:115-120. (Pubitemid 36197647)
105. Wang Z, Wu B, Kuhen KL, Bursulaya B, Nguyen TN, Nguyen DG, He Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2006;16:4174-4177.
106. De La Rosa M, Kim HW, Gunic E, Jenket C, Boyle U, Koh YH., Korboukh I, Allan M, Zhang W, Chen H, Xu W, Nilar S, Yao N, Hamatake R, Lang SA, Hong Z, Zhang Z, Girardet JL. Tri-substituted triazoles as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006;16:4444-4449. (Pubitemid 44094093)
107. Jordao AK, Afonso PP, Ferreira VF, De Souza MC, Almeida MC, Beltrame CO, Paiva DP, Wardell SM, Wardell JL, Tiekink ER, Damaso CR, Cunha AC Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture. Eur J Med Chem 2009;44:3777-3783.
108. Carretero OA, Oparil S. Essential hypertension. Part I: Defnition and etiology. Circulation 2000;101:329-335. (Pubitemid 30054162)
109. Guyton & Hall, and John E. Hall Textbook of Medical Physiology, 11th Edition, Elsevier 2005;7:220.
110. Chobanian AV, Bakris GL, Black HR. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
111. Kakefuda A, Suzuki T, Tobe T, Tsukada J, Tahara A, Sakamoto S, Tsukamoto S. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl- 1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. J Med Chem 2002;45:2589-2598. (Pubitemid 34595229)
112. Okazaki T, Suga A, Watanabe T, Kikuchi K, Kurihara H, Shibasaki M, Fujimori A, Inagaki O, Yanagisawa U. Studies on nonpeptide angiotensin II receptor antagonists I: Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents. Chem Pharm Bull 1998;46:69-78. (Pubitemid 28099429)
113. Vega JA, Mortimer AM, Tyson PJ. Conventional antipsychotic prescription in unipolar depression, I: An audit and recommendations for practice. Te Journal of clinical psychiatry 2003;64:568-574. (Pubitemid 36618287)
114. Varvaresou A, Siatra-Papastaikoudi T, Dalla TA, Tsantili-Kakoulidou A, Vamvakides A. Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2,4-triazole. Farmaco 1998;53:320-326. (Pubitemid 28308077)
115. Roshan JB, Schulkin J. From fear to pathological anxiety. Psychol Rev 1998;105:325-350.
116. Carling RW, Moore KW, Street LJ, Wild D, Isted C, Leeson PD, Tomas S, O'Connor D, McKernan RM, Quirk K, Cook SM, Atack JR, Waford KA, Tompson SA, Dawson GR, Ferris P, Castro JL. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4- triazolo[3,4-a] phthalazines and analogues: high-afnity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. J Med Chem 2004;47:1807-1822. (Pubitemid 38380925)
117. Akbarzadeh T, Tabatabai SA, Khoshnoud MJ, Shafaghi B, Shafee A. Design and synthesis of 4H-3-(2-phenoxy)phenyl-1,2,4-triazole derivatives as benzodiazepine receptor agonists. Bioorg Med Chem 2003;11:769-773. (Pubitemid 36132220)
118. Carling RW, Madin A, Guiblin A, Russell MG, Moore KW, Mitchinson A, Sohal B, Pike A, Cook SM, Ragan IC, McKernan RM, Quirk K, Ferris P, Marshall G, Tompson SA, Waford KA, Dawson GR, Atack JR, Harrison T, Castro JL, Street LJ. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fuorophenyl) -1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acidA (GABAA) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 2005;48:7089-7092. (Pubitemid 41743620)
119. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-infammatory actions and cardiac efects. Clin Exp Allergy 2002;32:489-498. (Pubitemid 34429565)
120. 1 agents. Pharmazie 2009;64:5-9.
121. 1-antihistaminic agents. Bioorg Med Chem Lett 2005;15:1877-1880. (Pubitemid 40380751)
122. Fishbein M. Anesthesia. Te New Illustrated Medical and Health Encyclopedia. amazon.co.uk 1976:87. 1976:87.
123. Vazzana I, Boido A, Sparatore F, Di Carlo R, Raso GM, Pacilio M. Preparation and local anaesthetic activity of N-[2-(tert-amino) ethyl]-and N-(lupinyl)-benzotriazol-1/2-ylacetamides. Farmaco 1997;52:131-139. (Pubitemid 27278536)
124. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. Te global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-217. (Pubitemid 40388051)
125. Mishra N, Arora P, Kumar B, Mishra LC, Bhattacharya A, Awasthi SK, Bhasin VK. Synthesis of novel substituted 1,3-diaryl propenone derivatives and their antimalarial activity in vitro. Eur J Med Chem 2008;43:1530-1535. (Pubitemid 351885216)
126. Tron GC, Pirali T, Billington RA, Canonico PL, Sorba G, Genazzani AA. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Res Rev 2008;28:278-308. (Pubitemid 351281190)
127. Wender PH, Handy ST, Wright DL. Towards the ideal synthesis. Chem Ind 1997;19:765-768.
128. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 2001;40:2004-2021.
129. Kolb HC, Sharpless KB. Te growing impact of click chemistry on drug discovery. Drug Discov Today 2003;8:1128-1137. (Pubitemid 37547919)
130. Appukkuttan P, Dehaen W, Fokin VV, Eycken D. A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. Org Lett 2004;6:4223-4225. (Pubitemid 39563449)
131. Feldman AK, Colasson B, Fokin VV. One-pot synthesis of 1,4-disubstituted 1,2,3-triazoles from in situ generated azides. Org Lett 2004;6:3897-3899. (Pubitemid 39523247)
132. Lee JW, Han SC, Kim JH, Ko YH, Kim K. Formation of rotaxane dendrimers by supramolecular click chemistry. Bull Kor Chem Soc 2007;28:1837-1840. (Pubitemid 350099244)
133. Cho M J, Cho MG, Huh SC, Kim SM, Lee K, Koh KO, Mang JY, Kim DY. Asymmetric Michael reaction of malonate derivatives with α,β- unsaturated ketones using chiral quaternary ammonium salts. Bull Kor Chem Soc 2006;27:857-862. (Pubitemid 43987783)
134. Mammen M, Choi SK, George M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl 1998;37:2754-2794. (Pubitemid 29008561)
135. Bennett I, Broom NJP, Bruton G, Calvert S, Clarke BP, Coleman K, Edmondson R, Edwards P, Jones D, Osborne NF, Walker G. 6-(substituted methylene)penenms, potent broad spectrum inhibitors of bacterial beta lactamase. J Antibiotics 1991;44:331-337.
136. Gifn MJ, Heaslet H, Brik A, Lin YC, Cauvi G. A copper (I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem 2008;51:6263-6270.
137. Pagliai F, Pirali T, Grosso ED, Brisco RD, Tron GC, Sorba G, Genazzani AA. Rapid synthesis of triazole-modifed resveratrol analogues via click chemistry. J Med Chem 2006;49: 467-470. (Pubitemid 43157480)
138. Winum JV, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran C T. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-α-D- glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett 2004;14:225-229. (Pubitemid 38010224)
139. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem 2006;49:6539-6548. (Pubitemid 44657448)
140. Chen Y Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 2008;51:3437-3448. (Pubitemid 351875000)
141. Kamal A, Shankaraiah N, Devaiah V, Reddy KL, Juvekar A, Sen S, Kurian N, Zingde S. Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine (PBD) conjugates employing click chemistry: DNA-binding afnity and anticancer activity. Bioorg Med Chem Lett 2008;18:1468-1473. (Pubitemid 351226525)
142. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18:1279-1295.
143. Elia G, Belloli C, Cirone F. In vitro efcacy of ribavirin against canine distemper virus. Antiviral Res 2008;77:108-113.
144. Bani-Sadr F, Carrat F, Pol S. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defc Syndr 2005;40:47-52. (Pubitemid 41233204)
145. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13:683-689. (Pubitemid 44401197)
146. Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 2002;80:86-95.
147. Bechir M, Schwegler K, Chenevard R. Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders. Auton Neurosci 2007;134:69-73. (Pubitemid 46891310)
148. Skelton KH, Nemerof CB, Owens MJ. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. J Neurosci 2004;24:9303-9312. (Pubitemid 39426167)
149. Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM. Alprazolam-related deaths in Palm Beach County. Am J Forensic Med Pathol 2005;26:24-27. (Pubitemid 40289267)
150. Miura M, Otani K, Ohkubo T. Identifcation of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica 2005;35:455-465. (Pubitemid 41044390)
151. Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW. Rufnamide: a new anti-epileptic medication. Expert Opin Pharmacother 2007;8:1931-1940.
152. Borras L, De Timary P, Constant EL, Huguelet P, Eytan A. Successful treatment of alcohol withdrawal with trazodone. Pharmacopsychiatry 2006;39:232. (Pubitemid 44899726)
153. Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache 2001;41:465-474. (Pubitemid 32466394)
154. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-1438.
155. Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T, Helfgott D, Holowiecki J, Stockelberg D, Goh Y, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole versus fuconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359. (Pubitemid 46148777)
156. Ullmann A, Lipton J, Vesole D, Chandrasekar P, Langston A, Tarantolo S, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fuconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347. (Pubitemid 46148776)
157. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani S, Ambrose P, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-1572.